Identification of treatment (imiquimod)-specific transcripts in the most intensive schedule (q12 × 4 (q12,4d), blue cohort). (a) A pairwise t-test (p value < 0.05) was applied to identify genes differentially expressed between pre-treatment and EOT biopsies from the same BCC belonging to the q12 × 4 (blue) cohort. The 1,578 genes identified were then tested for treatment specificity by identifying those differentially expressed between the blue group treated with imiquimod (TX) compared with temporally matched, vehicle control-treated EOT biopsies (combined blue and green groups (b) The remaining 637 treatment-specific genes were classified based on their significant expression also in the earlier q12 × 2 (orange) group as primary (65 genes) while the other ones were considered secondary. Finally, the same genes were also compared to a database of IFN-α-associated transcripts as described in the Materials and methods. In the same panel the 637 genes are shown in a supervised-sample hierarchical clustering of the genes. (c) Legend of samples, dashed and solid bars identify vehicle control or imiquimod-treated samples, respectively.